Ketamine Trial for Acute suicidality - pilot

Rationale: Suicide is currently one of the three leading causes of death in the Netherlands in people aged 15-44 and has a substantial impact on families and society (1). Nevertheless, to date no evidence based pharmacological intervention for acute suicidality exists. Subanesthetic doses of intravenous ketamine have been shown to immediately resolve depressive symptoms and suicidal ideation in depressed patients (2, 3). However, this effect was never investigated for suicidality per se. Herewith, we propose a multicenter double blind randomized placebo controlled trial in 100 subjects presenting with acute suicidality regardless of the underlying diagnosis, to test the hypothesis that a single dose of 75mg intranasal ketamine is able to diminish acute suicidal ideation and behaviour. Additionally, we will examine ketamine’s anti-suicidal mechanism of action by measuring plasma, serum and neuroimaging markers. This study may result into a readily available and easily applicable intervention for the treatment of acute suicidality. Objective: The objective of the main KETA-study is to test the hypothesis that a dose of 75mg of intranasal ketamine lowers suicidal ideation and behaviour significantly more than active placebo: midazolam. First, a feasibility pilot with 12 subjects, who will all receive ketamine, will be performed. Study design and population: This is a feasibility pilot study for the larger KETA-trial: a total of 12 subjects will be included. They will receive an intranasal dose of 75mg . At baseline and at 60 and 180 minutes, 1, 3 and 7 days after ketamine administration, the Beck Scale for Suicide Ideation will be administered. Blood will be taken at 0 and 180 minutes to assess fatty-acid profiles, Brain Derived Neurotrophic Factor (BDNF) and ketamine concentrations. One day after administration, in persons who provided informed consent for participation in the imaging study, magnetic resonance scans will be performed (diffusion tensor imaging (DTI), resting state functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS)). Prior to the RCT, we will perform a small-scale feasibility study in the UMCG (n=12), which is described in paragraph 8.3.1. Main study parameters/endpoints: Primary: Change in suicidality scores on the Beck Scale for Suicidal Ideation (BSSI) between baseline and 180 minutes after 75 mg intranasal ketamine. Secondary: Change in Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global Impression (CGI), the Systematic Assessment for Treatment Emergent Events (SAFTEE) and the Clinician Administered Dissociative States Scale (CADSS) (4), change in serum and plasma BDNF concentrations from 0 to 180 minutes, fatty acid concentrations at baseline, plasma ketamine concentrations at 180 minutes after intervention, functional and structural frontolimbic connectivity patterns, hippocampal volume and glutamate levels. Nature and extent of the burden and risks associated with participation is considered moderate: The expected side effects of 75mg intranasal ketamine are minor. The most commonly described side-effect is a feeling of dissociation. To date, no serious adverse event related to the intervention has occurred in low-dose ketamine trials for mood disorders. However, all participants that are to be included, have a high risk of attempting or committing suicide, therefore, the chance that a SAE might occur, is relatively high, and we will therefore classify the risk level of this study as moderate. The expected benefit may be significant in terms of immediate reduction of suicidal ideation and behaviour.

A dose of 75mg of intranasal ketamine lowers suicidal ideation

T0, T 1 hour, T3 hours, T1 day, T3 days, T7 days.

intranasal ketamine